Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00681044 · ClinicalTrials.gov registry record · Phase 2
HD Melphalan and SCT in Patients With IGDD or LCDD
A Phase 2 study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00681044 is a Phase 2 study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT00681044, a Phase 2 study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This phase II trial is studying the side effects of high-dose melphalan given together with stem cell transplant and to see how well it works in treating patients with immunoglobulin deposition disease or light-chain deposition disease.
Interventions
- DRUG melphalan
- BIOLOGICAL filgrastim
- PROCEDURE Stem Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00681044
The ClinicalTrials.gov registry entry for NCT00681044 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which melphalan is the first listed.
NCT00681044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00681044 about?
NCT00681044 is a clinical study titled "HD Melphalan and SCT in Patients With IGDD or LCDD". RATIONALE: Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be colle...
What is the current status of trial NCT00681044?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2006-10. Estimated completion is 2016-01.
What interventions are being tested in trial NCT00681044?
The interventions under investigation include: melphalan (DRUG), filgrastim (BIOLOGICAL), Stem Cell Infusion (PROCEDURE).
Who is sponsoring clinical trial NCT00681044?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.